Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H2 | P55055 | 1/20 | 0.59 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.54 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
| ▸ | RAB9A | P51151 | 1/20 | 0.47 |
| ▸ | TMEM97 | Q5BJF2 | 6/20 | 0.46 |
| ▸ | SIGMAR1 | Q99720 | 6/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | RIPK1 | Q13546 | 3/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.43 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.43 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.43 |
| ▸ | NAMPT | P43490 | 2/20 | 0.41 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.40 |
| ▸ | UCHL1 | P09936 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1285596 | 0.93 | NR1H2 (0.69) | NR1H2ESR2NPC1RAB9ATMEM97 | |
| SCHEMBL29407557 | 0.93 | NR1H2 (0.69) | NR1H2ESR2NPC1RAB9ATMEM97 | |
| SCHEMBL29407529 | 0.88 | ESR2 (0.70) | NR1H2ESR2NPC1RAB9ATMEM97 | |
| SCHEMBL168265 | 0.88 | ESR2 (0.70) | NR1H2ESR2NPC1RAB9ATMEM97 | |
| SCHEMBL29974005 | 0.87 | ESR2 (0.54) | NR1H2ESR2MAPK1HDAC1GPR119 | |
| SCHEMBL1650190 | 0.87 | ESR2 (0.54) | NR1H2ESR2MAPK1HDAC1GPR119 | |
| SCHEMBL1787313 | 0.85 | ESR2 (0.59) | NR1H2ESR2NPC1RAB9AGPR119 | |
| SCHEMBL15503125 | 0.84 | ESR2 (0.59) | NR1H2ESR2NPC1RAB9ATMEM97 | |
| SCHEMBL1648703 | 0.84 | ESR2 (0.76) | NR1H2ESR2NPC1RAB9ATMEM97 | |
| SCHEMBL29598893 | 0.84 | ESR2 (0.76) | NR1H2ESR2NPC1RAB9ATMEM97 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172416-A1 | AMIDINE DERIVATIVE | AJINOMOTO CO., INC. (JP) | 2011-07-14 | — | — | US | disclosed |
| EP-2311810-A1 | AMIDINE DERIVATIVE | Ajinomoto Co., Inc. (JP) | 2011-04-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172416-A1 | AMIDINE DERIVATIVE | SERPINC1, F12, F11 | NR1H2 2374/4885ESR2 4507/4885NPC1 3463/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.